KAP1 Promotes Proliferation and Metastatic Progression of Breast Cancer Cells

Joseph B. Addison1, Colton Koontz1, James H. Fugett1, Chad J. Creighton2, Dongquan Chen3, Mark K. Farrugia1, Renata R. Padon1, Maria A. Voronkova1, Sarah L. McLaughlin1, Ryan H. Livengood4, Chen-Chung Lin1, J. Michael Ruppert1, Elena N. Pugacheva1, and Alexey V. Ivanov1

Abstract

KAP1 (TRIM28) is a transcriptional regulator in embryonic development that controls stem cell self-renewal, chromatin organization, and the DNA damage response, acting as an essential corepressor for KRAB family zinc finger proteins (KRAB-ZNF). To gain insight into the function of this large gene family, we developed an antibody that recognizes the conserved zinc fingers linker region (ZnFL) in multiple KRAB-ZNF. Here, we report that the expression of many KRAB-ZNF along with active SUMOylated KAP1 is elevated widely in human breast cancers. KAP1 silencing in breast cancer cells reduced proliferation and inhibited the growth and metastasis of tumor xenografts. Conversely, KAP1 overexpression stimulated cell proliferation and tumor growth. In cells where KAP1 was silenced, we identified multiple downregulated genes linked to tumor progression and metastasis, including EREG/epiregulin, PTGS2/COX2, MMP1, MMP2, and CD44, along with downregulation of multiple KRAB-ZNF proteins. KAP1-dependent stabilization of KRAB-ZNF required direct interactions with KAP1. Together, our results show that KAP1-mediated stimulation of multiple KRAB-ZNF contributes to the growth and metastasis of breast cancer. Cancer Res; 75(2): 344–55. © 2014 AACR.

Introduction

Approximately 2,000 sequence-specific transcription factors are encoded in the human genome, including approximately 800 C2H2-type zinc finger proteins (ZNF; ref. 1). About half of these ZNFs contain the highly conserved KRAB repression domain (2, 3). KRAB family zinc finger proteins (KRAB-ZNF) and their corepressor KAP1 have coappeared in evolution in tetrapods (4). KRAB-ZNFs underwent unprecedented expansion in mammalian genomes, and KRAB motif represents one of the most rapidly evolving domains (5). Despite the large size of this family, only a few KRAB-ZNFs have been studied in sufficient detail to establish their biologic and molecular functions (6–9).

Most KRAB-ZNFs adopt simple protein architecture where the conserved N-terminal KRAB domain is linked with the sequence-specific DNA binding domain comprised of tandem arrays of the C2H2 type zinc fingers (2, 10). At the molecular level, the KRAB domain directly binds to KAP1, and this interaction is essential for KRAB-ZNF–mediated repression (11, 12). KAP1 is recruited to chromatin by KRAB-ZNFs (6, 13), and in turn functions as a scaffolding protein for histone- and DNA-modifying enzymes involved in establishing the silenced state of a gene (14, 15). In this process, KAP1 acts as an E3 SUMO ligase and undergoes auto-SUMOylation, which promotes its interaction with the repression machinery (16, 17).

Genetic knockout of KAP1 has revealed its multifaceted role in many organismal processes such as development, reproduction, and immune response. KAP1 is essential for differentiation of mouse stem cells in vivo (18, 19). Although the role of KAP1 in development could be attributed to the establishment of imprinted methylation patterns (19, 20) and the control of endogenous retroviral elements (7, 21), its function in adult tissues appears to be distinct (21–23).

KAP1 is a ubiquitously expressed nuclear protein, and its role in cancer is just beginning to emerge. Analysis of tissue microarrays demonstrated that KAP1 expression is increased during the clinical progression of 39% of invasive breast carcinomas in situ to metastasis in lymph nodes (24). High KAP1 mRNA expression has been found to be an independent prognostic factor for peritoneal carcinomatosis (25). Given the relevance of developmental cell fate regulators and stem cell pluripotency to cancer pathogenesis, understanding how KAP1 functions in cancer cells might be critical for developing future therapeutic strategies.

Overexpression of specific KRAB-ZNF genes in cancer has been documented (10). Several KRAB-ZNFs have been implicated in regulation of oncogenes and tumor suppressors in cell culture models, including p53 (26), MDM2 (27), Rb (28), BRCA1 (29), and pVHL (30). In breast cancer, three KRAB-ZNFs undergo gene amplification (31). High expression of 18 KRAB-ZNF genes have been associated with increased resistance of GIST tumors to...
KAP1 Stabilizes KRAB-ZNFs and Promotes Mammary Tumorigenesis

imatinib treatment (32). However, the expression patterns and functions of the majority of KRAB-ZNFs in breast cancer are still unknown.

Here, we showed that KAP1 and certain KRAB-ZNFs are frequently overexpressed in breast tumors at both mRNA and protein levels. Knockdown of KAP1 in breast cancer cells led to inhibition of cell proliferation, tumor growth, and metastasis. Mechanistically, we showed that KAP1 depletion results in decreased expression of multiple KRAB-ZNF proteins and deregulation of many cancer and metastasis-associated genes. These findings demonstrate that KAP1 and KRAB-ZNFs may play an important role in breast cancer and could be explored as targets for therapeutic intervention.

Materials and Methods

Generation of zinc finger linker antibody

The rabbit polyclonal zinc finger linker (ZnFL) antibody was raised against a mixture of Z1 and Z2 peptides. Z1 (Ac-CGGHGQ/K/EIRHTGEKPY[K/E]-amide) and Z2 (Ac-GHGQ/K/EIRHTGEKPY[K/E]-amide) peptides were synthesized and used for rabbit immunization and affinity purification of ZnFL antibody.

Cell lines and constructs

MDA-MB-231-luc-D3H2LN (MDA-MB-231LN) cells were purchased from Caliper Life Science. Primary HMECs were purchased from Lonza and Invitrogen. HMLE cells were kindly provided by Dr. Robert Weinberg (Massachusetts Institute of Technology, Cambridge, MA), S2 cells by Dr. Alexei Tulin (Fox Chase Cancer Center, Philadelphia, PA), AB9 and XTC cells by Dr. Neil Hukriede (University of Pittsburgh, Pittsburgh, PA), CEF and MEF cells by Dr. Daniel Flynn (West Virginia University, Morgantown, WV), KAP1 knockout MEFs (21) by Dr. Didier Trono (Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland). The other cell lines were purchased and authenticated by ATCC. shRNAs were expressed from pTRIPz vector and induced by addition of 0.5 μg/mL doxycycline for 7 days. FLAG-KAP1 WT and mutants (16) were expressed from pLlJ vector. ZNF10, 224, 317, 350 were expressed from pTRIPZ vector and induced by addition of 0.5 μg/mL doxycycline for 7 days. DIF-KAP1 WT and mutants (16) were expressed from pcDNA3-HA.

Cell proliferation assay

A total of 2 x 10^5 cells were plated in triplicates in 6-well plates, cultured for 2, 4, 6, and 8 days, trypsinized, and counted on Countess (Invitrogen).

Quantitative RT-PCR

Total RNA was extracted using the mirVana miRNA isolation kit in triplicates. Two micrograms of total RNA was reverse transcribed using SuperScriptIII and dT20 primer. Quantitative PCR (qPCR) was performed in an ABI-7500 Real-Time PCR Cycler and analyzed using ABI SDS2.06 software. Gene expression levels were normalized by the geometrical mean of UBC, RPL13A, PCNA, and tubulin genes relative to control. The primers and shRNAs are described in Supplementary Methods.

Western blotting and immunoprecipitation

Cells were lysed in nonreducing Laemmli buffer and total protein was quantified by BCA assay. The ProteoJet Cytoplasmic and Nuclear Protein Extraction Kit (Fermentas) was used for subcellular fractionation for Fig. 1C. Lysates with equal amount of total protein were separated on 4% to 12% Bis-Tris gels and transferred to a polyvinylidene difluoride (PVDF) membrane. Protein bands were detected using standard chemiluminescence techniques and quantified by the GeneTools software (Syngene). Breast OncoPair INSTA-Blot was purchased from Imgenex, cat. 1MB130a. Immunoprecipitation was performed in mIP (Fig. 1D) or RIPA buffer (Fig. 1E and 3E) as described (16). The antibodies are described in Supplementary Methods.

Animal studies and bioluminescence imaging

NOD.Cg-Ptkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were purchased from The Jackson Laboratory and fed doxycycline-containing diet (Bio-Serv) to maintain shRNA expression. Mice were injected with MDA-MB-231LN cells and imaged as described (33). Primary tumor and organs with metastases were collected at the end point of study and analyzed as described (33).

Microarray, proteomics, and bioinformatics analyses are described in Supplementary Methods.

Statistical analysis

Statistical analyses were performed with the Prism5 software (GraphPad) using the two-tailed Student t test.

Results

Characterization of a ZnFL polyclonal antibody

The limited availability of reagents has hindered analysis of KRAB-ZNF proteins to date. Perhaps as few as four antibodies capable of detecting endogenous levels of individual KRAB-ZNF proteins have been reported (6, 34, 35). After testing multiple commercial antibodies to many KRAB-ZNFs, we were able to detect endogenous levels of ZNF192 and ZNF274. Difficulty in detection of KRAB-ZNFs is likely due to their relatively low expression levels, a characteristic of many transcription factors (1). To overcome this problem and to analyze expression of the majority of KRAB-ZNFs simultaneously, we developed a pan-ZNF–specific antibody, referred to as the ZnFL antibody thereof. A unique structural feature of most C2H2-type ZNFs is a short and remarkably conserved ZnFL sequence, TGEKPYK/E, that connects two adjacent zinc fingers (Fig. 1A). More than 90% of all individual zinc fingers in human C2H2-type ZNFs, including approximately 350 KRAB-ZNFs, contain this or highly similar sequence (Supplementary Fig. S1; ref. 4). The ZnFL is present in each KRAB-ZNF with the frequency typically equal to the number of zinc fingers minus one (Fig. 1B). The median number of zinc fingers in human KRAB-ZNFs is 12 (2), providing multiple ZnFL epitopes in each KRAB-ZNF.

A rabbit polyclonal ZnFL antibody was raised using ZnFL consensus peptides as antigens, affinity purified, and validated by Western blotting (Fig. 1C and Supplementary Fig. S3). Nuclear and cytoplasmic fractions from cells from several species representing different classes of the eukaryotes were analyzed. As expected, ZnFL antibody did not detect ZNFs in yeast and reacted with only a few proteins in Drosophila cell lysates. However, strong ZnFL-specific signals were observed in the nuclear fractions from all vertebrate cells. The stronger signal in zebrafish lysates is likely due to the tetraploid nature of these cells and a higher content of nuclear proteins as evidenced by the strong histone H3 signal. Interestingly, only three weak ZnFL-reactive bands were detected in chicken cell lysates, suggesting that the avian ZNFs have diverged significantly in the structure of the zinc finger linker.
Indeed, alignment of zinc finger sequences across species revealed divergence of the avian sequence from the sequence of other species at the fourth and sixth positions (Supplementary Fig. S2). ZnFL-reactive protein bands were primarily in the nucleus, consistent with the notion that ZNFs are transcription factors. The monoclonal antibody raised to human KAP1 protein detected KAP1 in human, mouse and Xenopus cells (Fig. 1C). It did not recognize chicken KAP1 likely due to sequence divergence between the species. Consistent with the expected range of sizes for human ZNFs (4), the ZnFL antibody detected multiple protein bands in the range of 40 to 150 kDa in total cellular lysates from all human cell lines tested (Supplementary Fig. S3).

The interaction of ZnFL-reactive proteins with KAP1 was confirmed using coimmunoprecipitation (IP). Proteins from human mammary epithelial HMLE cells expressing FLAG-KAP1 were immunoprecipitated with the FLAG or control HA antibody (Fig. 1D). The ZnFL antibody detected many proteins in the FLAG immune complex but not in the control IP. Endogenous KRAB-ZNFs, ZNF192 and ZNF274, were specifically detected in the FLAG immune complex and served as positive controls. Most importantly, IP with FLAG antibody recovered the majority of the ZNF protein bands (Fig. 1D, compare lanes 4 and 8), suggesting that these correspond to ZNFs with the KRAB domain, i.e., KRAB-ZNFs. The reciprocal IP using the ZnFL antibody or control normal rabbit IgG was also performed. As expected, endogenous KRAB-ZNFs, ZNF192 and ZNF274, were present in the ZnFL IP but not the control IP. KAP1 was also detected in the ZnFL immune complex but not the control IP. Furthermore, the ZnFL antibody efficiently precipitated three randomly selected HA-tagged KRAB-ZNFs: ZNF224, ZNF317, and ZNF350 (Fig. 1E), indicating the potential to recognize most KRAB-ZNFs.

The identity of ZnFL antibody-recognized proteins was confirmed by mass spectrometry of control IgG and ZnFL immunoprecipitates. From 37 proteins specific to the ZnFL IP from MDA-MB-231LN breast cancer cells, 22 were ZNFs (Table 1 and Supplementary File 1) and 15 were abundant nonnuclear contaminants. Both, ZNF192 and ZNF274 are expressed in MDA-MB-231LN cells (Fig. 3B). The absence of ZNF274 in the mass spectrometry data suggested that the identified ZNFs are likely the most abundant or/and amenable to LC-MS/MS and the total number of 22 expressed ZNFs in these cells is an underestimation. These results clearly demonstrate that ZnFL antibody detects proteins consistent with sequence, expected size, subcellular localization, and expression pattern of ZNFs. Notably, the majority of the ZnFL-detected proteins coimmunoprecipitated with KAP1 (Fig. 1D), indicating that significant proportion of ZnFL-recognized bands represent KRAB-ZNFs.

KAP1 and KRAB-ZNFs are overexpressed in human breast tumors

TRIM28/KAP1 and KRAB-ZNFs expression in human breast cancer was first analyzed at the mRNA level. KAP1 was modestly overexpressed (1.3–2.1-fold) in breast carcinoma compared with normal tissue in several public array datasets (Supplementary...
KAP1 was upregulated in TCGA breast tumor data, with 525 samples profiled by Agilent mRNA expression arrays and 896 samples analyzed by RNA-Seq (Fig. 2A and Supplementary Fig. S4). The KAP1 level was higher in all four intrinsic breast cancer subtypes and in breast cancer metastases (Fig. 2A and B). Analysis of a mouse dataset comprised of 108 tumors from 13 different mouse models of breast cancer revealed that KAP1 was upregulated in all molecular tumor subtypes compared with normal tissue, 1.4-fold on average (Supplementary Fig. S5). KAP1 upregulation in breast tumors was consistent across multiple datasets but relatively modest in absolute fold change. Noteworthy, the basal level of KAP1 mRNA in normal breast tissue is relatively high and is comparable with the levels of such housekeeping genes as TUBA1A, PCNA, and HPRT1.

To determine if KRAB-ZNFs, which use KAP1 as a corepressor, are also overexpressed in breast cancer, we analyzed their expression in the two TCGA breast datasets. Of 365 annotated KRAB-ZNF genes, 343 were detected in the RNA-Seq dataset and 289 in the array dataset. Most KRAB-ZNF genes common for both datasets were regulated in tumors concordantly, although fold changes for upregulated genes in the RNA-Seq dataset were lower. Thus, 28 genes were upregulated >1.35-fold in the RNA-Seq dataset and 70 genes in the array dataset, and 48 of the upregulated genes were common to both datasets (>1.35-fold in at least one dataset, \( P < 0.05 \) in both). Eighty-one genes were downregulated >1.35-fold in the RNA-Seq dataset and 70 genes in the array dataset, and 64 downregulated genes were common to both datasets by the same criteria (Fig. 2C and Supplementary File 2). Only 10 KRAB-ZNF genes were upregulated in one dataset and downregulated in the other or vice versa. Less than a quarter of the differentially regulated KRAB-ZNFs, however, showed changes of more than 2-fold, suggesting that deregulation of rather multiple KRAB-ZNF genes simultaneously but at a modest level occurs in breast tumors. We also analyzed expression of a more diverse superfamily of non–KRAB-ZNF genes and found similar general trend (Supplementary Fig. S6; Supplementary File 2).

KAP1 protein expression was compared in surgical samples of matched normal–tumor pairs. The vast majority of the tumor samples demonstrated a 2- to 10-fold higher level of KAP1 protein

**Table 1.** Mass spectrometry identification of ZNFs immunoprecipitated by control IgG and ZnFL antibody

<table>
<thead>
<tr>
<th>Accession number</th>
<th>SpC</th>
<th>SpC</th>
<th>ZnFL</th>
<th>KRAB domain</th>
<th>SCAN domain</th>
<th>Number of ZFs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q15072</td>
<td>j</td>
<td>OZF/ZNF146</td>
<td>0</td>
<td>17</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Q5V52</td>
<td>j</td>
<td>ZNF691</td>
<td>0</td>
<td>16</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Q9HSH4</td>
<td>j</td>
<td>ZNF768</td>
<td>0</td>
<td>12</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Q7L534</td>
<td>j</td>
<td>ZNF771</td>
<td>0</td>
<td>10</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Q96N38</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q86W11</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q96N38</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q96N38</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q15072</td>
<td>j</td>
<td>OZF/ZNF146</td>
<td>0</td>
<td>17</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Q5V52</td>
<td>j</td>
<td>ZNF691</td>
<td>0</td>
<td>16</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Q9HSH4</td>
<td>j</td>
<td>ZNF768</td>
<td>0</td>
<td>12</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Q7L534</td>
<td>j</td>
<td>ZNF771</td>
<td>0</td>
<td>10</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Q96N38</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q86W11</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q96N38</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q96N38</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q15072</td>
<td>j</td>
<td>OZF/ZNF146</td>
<td>0</td>
<td>17</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Q5V52</td>
<td>j</td>
<td>ZNF691</td>
<td>0</td>
<td>16</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Q9HSH4</td>
<td>j</td>
<td>ZNF768</td>
<td>0</td>
<td>12</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Q7L534</td>
<td>j</td>
<td>ZNF771</td>
<td>0</td>
<td>10</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Q96N38</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q86W11</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q96N38</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Q96N38</td>
<td>j</td>
<td>ZNF714</td>
<td>0</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: SpC, spectral counts.

**Figure 2.** KAP1 and KRAB-ZNFs are overexpressed in breast tumors. A and B, analysis of KAP1 in TCGA breast RNA-Seq data from 105 normal and 798 tumor samples of different subtypes and metastases. Data shown as mean and 5% to 95% percentile. \( ** \), \( P < 0.0001 \), two-tailed t test. C, analysis of KRAB-ZNFs expression in TCGA breast array \( ( n = 527) \) and RNA-Seq \( ( n = 896) \) datasets, \( P < 0.05 \). D, Western blot analysis of KAP1 and KRAB-ZNFs in biopsy samples of matched normal(N)–tumor(T) pairs. TLR3 and GAPDH are shown for comparison. E, representative immunohistochemistry for KAP1 in normal breast and in invasive ductal carcinoma. Images from Human Protein Atlas: www.proteinatlas.org.
compared with their normal controls (Fig. 2D and Supplementary Fig. S7). Immunohistochemical analysis has documented elevated KAP1 levels in significant proportions of breast, lung, liver, gastric, and prostate tumors (Fig. 2E and see TRIM28 at www.proteinatlas.org), indicating that KAP1 overexpression is a common feature of many epithelial cancers.

To analyze KRAB-ZNF proteins expression in breast tumors, the same matched normal–tumor samples were probed with the ZnFL antibody. Interestingly, substantially higher levels of multiple KRAB-ZNFs were detected in most tumors compared with normal controls, and they correlated with KAP1 protein levels (Fig. 2D). These results indicate that KAP1 and multiple KRAB-ZNFs are frequently overexpressed in breast tumors at the mRNA level, but most profoundly at the protein levels.

KAP1, KAP1 SUMOylation, and KRAB-ZNFs are upregulated in human breast cancer cell lines

Analysis of gene expression in tissue samples is confounded by the complexity of tissue composition made up of multiple cell types and their relative contribution to the sum readout signal. To analyze pure cell populations, we compared KAP1 levels in two independent isolates of primary human mammary epithelial cells (HMEC), two immortalized mammary cell lines, HMLE and MCF10A, and a panel of 17 breast cancer cell lines representing luminal, basal, and claudin-low breast cancer subtypes. Similarly to the human patient data, KAP1 mRNA levels were elevated 1.5- to 3-fold in breast cancer cell lines compared with primary HMECs (Fig. 3A).

KAP1 protein was upregulated in most cancer cell lines by 2- to 4-fold when normalized to tubulin, with higher levels observed in luminal cells (Fig. 3B and C). For a comparison, we analyzed expression of established breast cancer oncogenes in the same cells. Interestingly, KAP1 protein was overexpressed at least as often as β-catenin (36) and more often than c-Met (Fig. 3B; ref. 37). The most striking difference was detected in the levels of SUMOylated KAP1 (Fig. 3B, D, and E; Supplementary Fig. S8). We have previously shown that conjugation of each SUMO moiety to the six SUMOylation sites in KAP1 adds approximately 15 kDa to the 100 kDa unmodified KAP1 protein and results in the appearance of a ladder of discrete higher molecular weight KAP1–SUMO conjugates (16). SUMO modification of KAP1 can only be detected in cells lysed in buffers containing SDS or NEM, an inhibitor of de-SUMOylating enzymes (Supplementary Fig. S9; Figure 3. KAP1 mRNA, protein, and SUMOylation are upregulated in breast cancer cell lines. The indicated cell lines representing luminal (L), basal (B), and claudin-low (C) breast cancer subtypes were analyzed for KAPI mRNA by qRT-PCR (A), KAPI protein (B and C) and KAP1 SUMOylation (B and D) by Western blotting. Arrow, 20 kDa protein band, which served as loading control. E-cadherin is shown as a reference for luminal and basal cells and as an additional loading control. Expression of β-catenin and c-Met oncoproteins as well as GAPDH and tubulin is elevated in cancer cells. KAPI-5, SUMOylated forms of KAPI. Graphs in C and D, densitometric quantification of B normalized by tubulin. In A, C, and D, levels for HMEC1 cells were assigned the relative value of 1. E, immunoprecipitation with control IgG and KAP1 antibody and Western blotting for SUMO2/3 and KAP1. Data, mean ± SD, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, two-tailed t test.
To confirm that the observed KAP1’S bands represent SUMOylated KAP1, we performed KAP1 IP and WB with SUMO2/3 antibody (Fig. 3E). When calculated as a fraction of total KAP1 signal, levels of SUMOylated KAP1 varied from 4% in HMECs up to 35% in MDA-MB-453 cells, with majority of cancer cell lines within 10% to 20% range (Supplementary Fig. S8). When normalized to tubulin, SUMOylated KAP1 was 5- to 30-fold higher in luminal and basal cancer cell lines compared with HMECs and immortalized cells (Fig. 3D). KAP1 SUMOylation level is an indicator of KAP1 corepressor activity (16, 17). These results suggest that not only KAP1 level, but also its activity is markedly increased in breast cancer cells.

Most breast cancer cells showed an increase in total ZnFl-specific signal compared with primary HMECs, with higher intensity bands observed in cells of luminal and basal subtypes (Fig. 3B), suggesting that, similar to KAP1, KRAB-ZNF proteins are broadly upregulated in breast cancer cell lines.

Genomic alterations of KAP1 and KRAB-ZNFs in human breast tumors

We analyzed frequencies of genomic alterations for KAP1 and all ZNF genes in the TCGA breast dataset (Supplementary File 3). Interestingly, only four missense mutations were identified in KAP1, which are likely passenger mutations. We identified five KRAB-ZNF genes mutated in more than 1% of cases and three of them were also downregulated in tumors at the mRNA level (ZNF208, ZNF41, and ZNF540). Some of the mutations in these three KRAB-ZNFs were nonsense mutations, while approximately half of the missense mutations were located in the zinc-finger DNA binding domain, suggesting that they are likely functionally inactivating mutations.

We identified six KRAB-ZNF genes at three separate loci that have undergone genomic deletions with frequencies between 8.3% and 43.9% of cases, and five of them were also downregulated in tumors at the mRNA level (ZNF778, ZNF595, ZNF141, ZNF721, and ZNF568; Supplementary File 3), suggesting that these are likely loss-of-function events. We identified a cluster of five KRAB-ZNF genes at 1q44 that has undergone genomic amplification in 45.3% of cases, and three of these genes were also upregulated in tumors at the mRNA level (ZNF695, ZNF658, and ZNF124), suggesting that these are likely gain-of-function events. In general, non–KRAB-ZNF genes followed similar patterns of mutations and gains/losses to those of KRAB-ZNFs (Supplementary File 3).

These results indicate that a small number of KRAB-ZNF genes are genetically altered in breast cancer. The identified genes should be functionally validated as cancer gene candidates in the future.

KAP1 positively regulates the protein levels of multiple KRAB-ZNFs

A positive correlation between KAP1 and KRAB-ZNF protein levels was consistently observed (Fig. 2D; 3B; Supplementary Fig. S3). To evaluate if KAP1 controls the expression of KRAB-ZNFs, KAP1 was inhibited using multiple shRNAs in a set of breast cancer cell lines of luminal (ZR75-1), basal (MDA-MA-468), and claudin-low (MDA-MB-231LN) subtypes as well as in "normal" mammary epithelial cells (HMLE; Fig. 4A; Supplementary Fig. S10). Surprisingly, we found that expression of multiple KRAB-ZNF proteins decreased significantly in KAP1-depleted cells and in KAP1 knockout fibroblasts, and conversely increased in cells overexpressing exogenous KAP1. The increase in KRAB-ZNFs levels was also induced by the repression-impaired KAP1 M2 mutant, suggesting that the upregulation likely occurs at posttranscriptional level (Fig. 4A).

Microarray expression profiling revealed only modest changes in expression of a few KRAB-ZNF genes in KAP1-depleted MDA-MB-231LN cells (Supplementary File 4). Previous microarray experiments conducted in multiple cell lines with KAP1 knockdown or in mouse tissues with KAP1 knockout yielded similar findings—marginal (<2-fold) changes in expression of a limited number of KRAB-ZNFs (22, 23, 38). Furthermore, ZNF192 protein decreased significantly upon KAP1 depletion in HMLE and ZR75-1 cells without changes in ZNF192 mRNA (Fig. 4B). These results suggested that the decrease of multiple KRAB-ZNF proteins following KAP1 knockdown is largely posttranscriptional.

To analyze if KRAB-ZNF proteins are degraded faster in the absence of KAP1, we treated cells with the proteasome inhibitor MG-132. Indeed, the expression level of multiple KRAB-ZNFs was elevated in KAP1-depleted cells following inhibition of posttranslational degradation to the same level as in control cells. The level of ZNF192 protein was similarly rescued (Fig. 4C, compare lanes 2 and 4). At the same time, the levels of KAP1 and control GAPDH proteins decreased slightly (Fig. 4C). These results suggest that KAP1 regulates KRAB-ZNF proteins stability.

Interaction with KAP1 protects the KRAB-ZNFs from posttranslational degradation

KAP1 binds directly to the KRAB domain (12) and can potentially stabilize KRAB-ZNFs through direct protein–protein interaction. In rescue experiments, we infected HMLE shKAP1 cells with lentiviruses expressing shRNA-resistant KAP1 cDNAs. As expected, reexpression of wild-type KAP1 resulted in elevated expression of multiple KRAB-ZNFs (Fig. 5A). Expression levels of KRAB-ZNFs were also rescued by reconstitution with KAP1 mutants that are impaired in repression function, i.e., the M2 mutant, which is deficient in interaction with HP1 (39), and the K6R mutant, which is SUMOylation deficient (Fig. 5A; Supplementary Fig. S11; ref. 16). This result confirmed that KAP1-dependent regulation of KRAB-ZNF protein levels was posttranscriptional. However, reexpression of a KAP1 mutant deficient in KRAB binding, the C2 mutant (16, 40), failed to restore KRAB-ZNFs expression levels, indicating that direct KAP1 binding to the KRAB domain is required for KRAB-ZNFs protein stabilization. We obtained similar results by transfection of KAP1 mutants into KAP1−/−MEFs (Supplementary Fig. S12).

In a complementary experiment, two different KRAB-ZNFs (ZNF10/KOX1 and ZNF350/ZBRK1) were transiently transfected into control and KAP1-depleted cells. Both wild-type ZNF10 and ZNF350 were expressed at significantly lower levels in KAP1-depleted cells compared with control cells (Fig. 5B), indicating that KRAB-ZNFs expression depends on the level of endogenous KAP1. The difference in KRAB-ZNFs levels was not due to variation in transfection efficiency since the expression of cotransfected GFP was similar in both cell lines. To further establish mechanism, ZNF10 and ZNF350 mutants were analyzed. The DV point mutation (DV->AA) in the KRAB domain impairs interaction with KAP1 and its repression activity (11, 12). The DV mutants were expressed at much lower levels than the corresponding wild-type KRAB-ZNFs in control cells, indicating that binding of KRAB-ZNFs to KAP1 is critical for expression. A KRAB-only variant of ZNF10 (KRAB) could be expressed in control cells, but was almost undetectable in the absence of KAP1. Expression of a
mutant of ZNF350 lacking the KRAB domain (dK) did not significantly differ between control and KAP1-depleted cells. These results strongly support the conclusion that the presence of the KRAB domain, which is essential for KAP1 binding, is required for efficient KRAB-ZNFs expression.

To confirm that the observed positive regulation of multiple KRAB-ZNFs by KAP1 was due to changes in KRAB-ZNFs protein stability, HMLE cells were treated with the protein synthesis inhibitor cycloheximide and KRAB-ZNFs degradation rate was analyzed. Levels of multiple KRAB-ZNFs decreased approximately 35% in control cells and approximately 60% in KAP1-depleted cells 4 hours following cycloheximide addition. The levels of endogenous ZNF192 protein decreased in a similar fashion (Fig. 4C and D), indicating that KRAB-ZNFs degrade faster in the absence of KAP1. The level of KAP1 and control GAPDH did not change significantly. In sum, these results indicate that KRAB-ZNF proteins undergo rapid proteasome-dependent turnover characteristic to transcription factors and that direct binding of KAP1 to KRAB-ZNFs protects from proteasomal degradation.

KAP1 promotes cell proliferation, tumor growth, and metastasis

To investigate if elevated KAP1 level in tumors is functionally linked to the malignant characteristics of cancer cells, the effect of KAP1 knockdown was analyzed. KAP1 depletion led to a decrease in cell proliferation in all the cell lines examined. Strong growth inhibition was also observed in Kap1 knockout MEFs (Fig. 6A). Conversely, overexpression of exogenous wild-type KAP1, but not the functionally impaired KAP1 M2 mutant stimulated cell growth (Fig. 6B), indicating that increased KAP1 levels and its repression activity promote cell proliferation.

To assess the role of KAP1 in tumorigenicity in vivo, MDA-MB-231LN cells were used in orthotopic xenograft mouse model. Injection of cells expressing control shRNA into the mammary fat pad of NSG mice resulted in rapid tumor growth as reported previously (33). Inhibition of KAP1 expression using shRNA reduced tumor growth significantly (Fig. 7A; Supplementary Fig. S13). Conversely, overexpression of exogenous KAP1 resulted in a stimulatory effect on tumor growth (Fig. 7B). These results indicate that KAP1 is a critical component promoting growth of tumor cells in vivo.

The number of lung metastases was scored in tumor-bearing mice. KAP1-knockdown tumors produced fewer metastatic colonies and KAP1-overexpressing tumors produced more metastatic colonies than controls (Fig. 7C and D). Because metastasis in these experiments simply correlated with tumor growth, an independent experiment to determine if KAP1 affects lung colonization following tail vein injection was performed. There was a significant decrease in lung bioluminescence in mice xenografted with KAP1 knockdown cells compared with control cells (Fig. 7E).
and F). These findings demonstrate that KAP1 depletion also inhibits metastatic outgrowth in lungs.

**KAP1 regulates expression of genes promoting tumor growth and metastasis**

To investigate the mechanisms by which KAP1 potentially promotes tumor growth and metastasis, we analyzed our microarray data from KAP1-depleted MDA-MB-231LN cells (Supplementary File 4). The genes for PTGS2/COX2, EREG/epiregulin, MMP1, and MMP2 have been previously identified in the lung metastasis gene signature derived from MDA-MB-231LM2 cells as essential factors of aggressive malignant and metastatic behavior (41, 42). Using qRT-PCR, we further confirmed their downregulation in MDA-MB-231LN and HMLE cells following KAP1 knockdown. Conversely, we found upregulation of some of these genes in cells overexpressing wild-type KAP1 (Fig. 7G and H), suggesting that their expression is specifically influenced by KAP1. Changes of COX2 and CD44 expression were confirmed by Western blotting (Fig. 7I). Together, these data indicate that KAP1 regulates expression of multiple genes promoting tumor growth and metastasis.

**Discussion**

Elevated expression of KAP1 mRNA has been reported in lung and gastric cancers (25, 43). Herein, we demonstrate that KAP1 is overexpressed in the majority of breast tumors and breast cancer cell lines, at both the mRNA and protein levels (Fig. 2; 3; Supplementary Figs. S4 and S5). Interestingly, although KAP1 mRNA is consistently but modestly overexpressed in cancer cells, KAP1 protein is upregulated at significantly higher levels (Fig. 2D and 2E; Supplementary Fig. S7), suggesting that posttranscriptional mechanism(s) could also be at play. In this regard, KAP1 SUMOylation, which is a major indicator of KAP1 repression activity (16, 17), is dramatically increased in cancer cells (Fig. 3; Supplementary Fig. S8) and may potentially account for higher KAP1 protein levels. In general, we observed a direct correlation between KAP1 protein and its SUMOylation levels (Fig. 3C and 3D; Supplementary Fig. S3). SUMOylation can compete for the same lysine residues with ubiquitylation and thus may inhibit ubiquitin-dependent protein degradation (44).

KRAB-ZNF genes constitute one fifth of all human transcription factors (1, 3). Lack of reagents for detection of endogenous levels of KRAB-ZNF proteins has significantly impeded elucidation of their functions. We have developed and characterized a potent ZnFL antibody directed to a highly conserved TGEKPY zinc finger linker and demonstrated that this antibody is capable of detecting multiple ZNF proteins. A similar approach was recently used to develop an antibody to a phosphorylated form of the TGEKPY motif (45). We confirmed the sensitivity and specificity of the ZnFL antibody using multiple approaches (Fig. 1, Table 1). Overexpression of certain KRAB-ZNF genes in cancer has been documented (10, 31, 32). Here, we analyzed two large TCGA...
Addison et al.

breast datasets and found that dozens of KRAB-ZNFs were upregulated, whereas dozens others were downregulated in breast tumors. Expression of a much smaller number of KRAB-ZNFs changed markedly (>2-fold; Fig. 2C). At the same time, multiple KRAB-ZNF proteins detected by the ZnFL antibody were overexpressed dramatically in breast tumors (Fig. 2D), suggesting that they could be upregulated at the protein rather than mRNA level.

Stabilization of individual proteins via assembly into functional multiprotein complexes is a common phenomenon. Stabilization of a sequence-specific transcription factor upon binding to its corepressor has been documented for E2F-Rb (46), p53-Sin3a (47), and RUNX1-Sin3a (48) interactions. Stabilization is typically achieved via inhibition of ubiquitin-dependent proteasome mediated degradation. Herein, we showed that multiple KRAB-ZNFs undergo rapid proteasome-dependent turnover and are stabilized upon binding to their corepressor KAP1 (Fig. 4 and 5). Therefore, significant upregulation of KRAB-ZNFs observed in breast tumors (Fig. 2D and E) is likely due to their stabilization by elevated KAP1. Dramatic decrease in the expression of dozens of KRAB-ZNF transcriptional repressors could also explain constitutive chromatin relaxation and reactivation of endogenous retroviral repeats observed in KAP1-deficient cells (21, 49).

Previous analyses of the KAP1 role in cancer cell proliferation yielded contradictory results (25, 43). Here, we used multiple

Figure 6. KAP1 promotes cell proliferation in vitro. A and B, growth curves for the cell lines characterized in Fig. 4A. Data, mean ± SEM. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$, two-tailed $t$ test.
shRNAs to knockdown KAP1 in four cell lines and showed that loss of KAP1 inhibited cell proliferation in all cases. Concordantly, overexpression of KAP1 yielded a complementary growth-stimulatory effect (Fig. 6). Consistent with the in vitro studies, inhibition of KAP1 slowed tumor growth and metastasis of MDA-MB-231LN cell xenografts in vivo (Fig. 7).

The mechanism by which KAP1 promotes cell proliferation and tumor growth is unknown but likely involves the action of KAP1-regulated genes. Here, we showed that KAP1 affects expression of many genes implicated in tumor progression and metastasis, particularly PTGS2/COX2, EREG/epiregulin, MMP1, and MMP2 that were previously linked to aggressive tumor behavior (Fig. 7; refs. 41, 42). Identity of individual KRAB-ZNFs involved in regulation of these genes and whether it occurs through direct or indirect mechanism remain to be determined in future studies.

Altogether, we showed that KAP1 is an important positive regulator of cell proliferation and tumor growth. This study suggests that anti-KAP1 drugs should be developed for anticancer therapy. An inhibitor disrupting transcription factor BCL6 with its corepressor SMRT has been shown to be effective against diffuse large B-cell lymphoma in vivo (50). This opens the possibility that small-molecule inhibitors of the KRAB-KAP1 interaction could be developed and potentially be used therapeutically.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Figure 7.
KAP1 promotes tumor growth and metastasis and regulates expression of cancer-associated genes. A and B, tumor growth curves of orthotopically injected MDA-MB-231LN cells: shControl (n = 4), shKAP1-4 (n = 5), vector control (n = 4). C and D, quantification of metastases in lungs of the animals in A and B. E, bioluminescent images of mice injected intravenously with the indicated MDA-MB-231LN cell lines at 3 weeks postinjection. F, quantitation of E, G and H, qRT-PCR of genes promoting tumor growth and metastasis in the indicated cell lines. I, Western blot analysis of COX2 and CD44 in the indicated cell lines. B2M, loading control. Data, mean ± SEM; *, P < 0.05; **, P < 0.01, two-tailed t test.
Addison et al.

Authors’ Contributions
Conception and design: J.B. Addison, A.V. Ivanov
Development of methodology: J.B. Addison, E.N. Pagacheva, A.V. Ivanov
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.B. Addison, C. Koontz, J.H. Fugett, M.K. Farmiga, MA. Voronkova, S.L. McLaughlin, R.H. Livengood, J.M. Ruppert, E.N. Pagacheva, A.V. Ivanov
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.B. Addison, C. Koontz, C.J. Creighton, D. Chen, R.R. Padon, M.A. Voronkova, A.V. Ivanov
Writing, review, and/or revision of the manuscript: J.B. Addison, D. Chen, S.L. McLaughlin, R.H. Livengood, E.N. Pagacheva, A.V. Ivanov
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.B. Addison, C.-C. Lin, A.V. Ivanov
Study supervision: J.B. Addison, A.V. Ivanov

Acknowledgments
The authors thank Rachel Romero, Erika Thompson, Icel Cavis, Garrett Butler, Nadia Ahmed, Fengiu Chen, and Yuriy Loskutov for technical assistance.

Wioletta Szasz-devedorowski for carrying out the microarray experiments. Drs. Michael Schaller and Peter Stoilov for critically reading the manuscript, and Drs. Robert Weinberg, Alexei Tulin, Neil Hukriede, Daniel Flynn, and Didier Trono for providing reagents.

Grant Support
This work was supported by grants from the Susan G. komen Foundation (KG10530 to A.V. Ivanov; KG100539 to E.N. Pagacheva) and from NIH/NCI (R01CA148671 to E.N. Pagacheva; P30CA125132 to C.J. Creighton), and in part from NIH/NCCR (5P20ROI01440), and NIH/NV-INBBRE (5P20GM103434).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 1, 2014; revised October 20, 2014; accepted November 5, 2014; published OnlineFirst November 24, 2014.

References


KAP1 Promotes Proliferation and Metastatic Progression of Breast Cancer Cells


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-1561

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/11/22/0008-5472.CAN-14-1561.DC1

This article cites 50 articles, 24 of which you can access for free at:
http://cancerres.aacrjournals.org/content/75/2/344.full.html#ref-list-1

This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/75/2/344.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.